#1Third Quarter 2020 Corporate update and financial results November 10, 2020 A 121 HI 3 Ax 11 BIONTECH#2Forward-looking statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the Company's views with respect to the potential for mRNA and other pipeline therapeutics; BioNTech's efforts to combat COVID-19; the collaborations between BioNTech and Pfizer and Fosun to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our continuing Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data for BNT162, BNT311 and our other product candidates, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential approval or Emergency Use Authorization with respect to our BNT162 program; the timing for submission of BNT162 manufacturing data to the FDA; the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021 and orders received to-date; the planned next steps in BioNTech's pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTech's product candidates and expectations for data announcements with respect to BioNTech's product candidates; BioNTech's expectations with respect to interactions with regulatory authorities such as FDA and EMA, including the potential approval of BioNTech's or its collaborators' current or future drug candidates; expected royalty and milestone payments in connection with BioNTech's collaborations; BioNTech's anticipated cash usage for fiscal year 2020 and beyond; the creation of long-term value for BioNTech shareholders; and the impact of COVID-19 on clinical trials and business operations, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expects," "plans," "potential," "target," "continue" and variations of these words or similar expressions are intended to identify forward-looking statements. Such statements are based on the current beliefs and assumptions of the management team of BioNTech and on the information currently available to the management team of BioNTech and are subject to change. The Company will not necessarily inform you of such changes. These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause the Company's actual results, performance or achievements to be materially different than any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the Company's ability to discover and develop its novel product candidates and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates; actions of the Company's collaborators regarding continued product development and product commercialization; actions of regulatory authorities, which may affect the initiation, timing and progress of clinical trials or the ability of the Company to obtain marketing authorization for its product candidates; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of our ongoing BNT162 trial or in larger, more diverse populations upon commercialization; the Company's ability to obtain, maintain and protect its intellectual property; the Company's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; competition from others using technology similar to the Company's and others developing products for similar uses; the Company's ability to manage operating expenses; the Company's ability to obtain additional funding to support its business activities and establish and maintain its existing and future collaborations and new business initiatives; the Company's dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the outcome of litigation; and unexpected expenditures. Any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The mRNA vaccines and other product candidates discussed in this slide presentation are investigational products being developed by BioNTech and its collaborators and are not currently approved by the FDA, EMA or any other regulatory authority. 2 BIONTECH#3● Agenda 3 Q3 Highlights BNT162 (COVID-19 vaccine program) Oncology Pipeline Update Financial Update and Outlook BIONTECH#4Q3 2020 Highlights BNT 162 COVID-19 Vaccine Program 4 Oncology Pipeline Financial Update and Outlook 1 ● ● ● Achieved Success in First Interim Analysis from Phase 3 Study No serious adverse events with mild to moderate tolerability profile observed to date Rolling submissions ongoing to EMA, MHRA (UK) and Health Canada On track for Emergency Use Authorization submission to FDA as early as the third week of November ● Initiated clinical trials in Japan and China to support potential local approval Acquired GMP facility in Marburg, Germany intended to increase production capacity in 2021 Commercial launch planning underway with global partners Pfizer and Fosun Pharma Promising early Phase 1 data for Next Gen Immunomodulator (BNT311) at SITC 2020 Early Phase 1 data presented for BNT131 (SAR 441000) at SITC and BNT114 at ESMO IND approval granted for randomized Phase 2 trial of iNeST (BNT122) in adjuvant CRC First patient dosed in Phase 1/2a trial of BNT411 in SCLC Closed equity and debt financings and secured grant commitments of approximately $1.2 billion¹ (€1.0 billion) in combined gross proceeds, resulting in net cash receipts of $0.8 billion¹ (€0.6 billion) in the third quarter Cash position of $1.2 billion¹ (€1.0 billion) on the balance sheet at end of Q3 2020 Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020 BIONTECH#5● ● Agenda 5 Q3 Highlights BNT162 (COVID-19 vaccine program) Oncology Pipeline Update Financial Update and Outlook BIONTECH#6COVID-19 vaccine development timeline DO COVID-19 mRNA Vaccine Program Initiation January 27, 2020 SARS-CoV-2 Genetic Sequence Made Public January 12, 2020 6 Collaborations Fosun Pharma: March 16, 2020 Pfizer: March 17, 2020 UU Candidate/ Dose Selection BNT162b2 July 24, 2020 Phase 1/2a Trial Germany Started April 23, 2020 • Up to 200 subjects aged 18-55 U.S. Started May 4, 2020 Up to 360 subjects aged 18-85 DI Initiated Pivotal Phase 2b / 3 Trial July 27, 2020 Start with up to 44,000 subjects UU FDA Fast Track designation July 13, 2020 Primary Efficacy Endpoint: To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 in participants with (and without) evidence of infection before vaccination Initiated Rolling Submissions EMA: October 6, 2020 Canada: October 7, 2020 UK: October 9, 2020 Interim analysis finds evidence of efficacy November 9, 2020 Interim analysis finds more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection BIONTECH#7BNT162b2 Phase 3 trial ြ 7 Vaccinated group ၅၀ ၅၀ ၅၀ ၅၀ Jo Jo Jo 1⁰]⁰]⁰ ြ ြ ၁၅ဝ ၅ဝ၂ဝ၅ဝ BNT 162b2 Up to 44,000 participants 21 days apart Healthy participants 18-85 (+16-17,12-15) yrs of age Active surveillance 7 for potential COVID-19 symptoms TRIGGERING telehealth or in- person visit and nasal swab Number of confirmed COVID-19 cases ≥ day 7 post dose 2 Placebo group ြ oooo ြ ၂၀ ၂၀ ၂၀ ၂၀ ၂၀ ၂၀ Jo Jo Jo Jo Jo Jo Jo Jo Jo Jo Jo Jo Interim analysis of unblinded data by independent data monitoring committee on Nov 8, 2020: 94 disease cases accrued, split of disease cases indicates >90% Vaccine Efficacy Benign safety profile Final efficacy analysis at 164 disease cases expected end of November, 2020 Vaccinated participants will continue to be monitored for up to 2 years C Primary Efficacy Objectives Efficacy against confirmed COVID-19 in participants without evidence of infection before vaccination Efficacy against confirmed COVID-19 in participants with and without evidence of infection before vaccination 43,538 participants enrolled 38,955 received 2nd dose Race/Ethnicity Asian Black Hispanic/Latinx Overall Study 5% 10% 26% Native American Data as of November 08th, 2020 0.8% BIONTECH#8BNT162: Global development program expanded to additional regions Phase 2/3¹ 8 Regulatory submissions on a rolling basis Ongoing trials Phase 2/3¹ ¹Phase 1/2 remains ongoing in U.S. and EU Phase 2/3 Phase 2/3 Phase 2/3 Phase 2/3 Phase 1/2 Phase 1 Regulatory submission on a rolling basis to EMA, MHRA (UK) and Health Canada initiated in October BIONTECH#9BNT162: Global commercial supply commitments* ● 9 > 570 million doses committed* for 2020 and 2021 in 13 countries and the EU with an option to purchase an additional 600 million doses Additional commercial discussions ongoing with multiple countries and supranational organizations including COVAX * Subject to clinical success and regulatory approval Region Canada EU Commercial supply commitments* Number of Doses Not disclosed 200 million with option for additional 100 million 120 million 30 million 100 million with option for additional 500 million Japan United Kingdom United States Nine additional countries Not disclosed Order value Not disclosed Not disclosed Not disclosed Not disclosed $1.95 billion for first 100 million doses Not disclosed BIONTECH#10BNT162: Distribution model Packaging Thermal shipping and GPS-tracking Thermal shipper (packaging designed to maintain crucial conditions) keeps product at ultra-low temperature for up to 10 days if stored at +15°C to +25°C without opening and up to 15 days if opened and then re-iced 10 Distribution Specialized supply chain providers for air and ground shipping. Manufacturing Site Distribution Center Point of Care - Storage at Point of Care WOW BUT Sonte Thermal Shipper BNT162b2 can be stored for up to 15 days on re- icing Ultralow Temperature Freezer Commercially available Store BNT162b2 as frozen liquid at -700C (+/- 100C) for up to 6 months Refrigerator (+2-8°C) BNT162b2 can be stored for up to 5 days after transfer from shipper or freezer Stability testing of BNT162b2 ongoing BIONTECH#11● ● Agenda 11 Q3 Highlights BNT162 (COVID-19 vaccine program) Oncology Pipeline Update Financial Update and Outlook BIONTECH#12Oncology pipeline: Expanded to 11 product candidates in 12 clinical trials. Drug class mRNA Antibodies SMIM ³ Platform 12 Fix Vac (fixed combination of shared cancer antigens) iNeST (patient specific cancer antigen therapy) Intratumoral Immunotherapy Next-Gen CP² Immunomodulators Targeted Cancer Antibodies Toll-Like Receptor Binding Product Candidate BNT111 BNT112 BNT113 BNT114 BNT115 R07198457 (BNT122) SAR441000 (BNT131) GEN 1046 (BNT311) GEN1042 (BNT312) BNT321 (MVT-5873) BNT411 Indication (Targets) advanced melanoma prostate cancer HPV16+ head and neck cancer¹ triple negative breast cancer ovarian cancer¹ 1L melanoma multiple solid tumors solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFN a) multiple solid tumors (PD-L1x4-1BB) multiple solid tumors (CD40x4-1BB) pancreatic cancer (sLea) solid tumors (TLR7) 1BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials. 2Checkpoint Inhibitor. 3Small Molecule Immunomodulators. Pre- clinical Phase 1 Phase 2 Rights / Collaborator fully-owned (Regeneron) fully-owned fully-owned fully-owned fully-owned Genentech (global 50:50 profit/loss) Sanofi (global profit/loss share) Genmab (global 50:50 profit/loss) fully-owned fully-owned ↑ BNT111: Clinical data published in Nature (July 2020); subsequent announcement of Regeneron collaboration BNT114 data update for TNBC- MERIT trial at ESMO Virtual Congress 2020 BNT 131 data update from Phase 1 presented at SITC BNT311 Interim update from Phase 1 presented at SITC BNT411 FPD in Phase 1/2 trial in ES-SCLC BIONTECH#13We plan to initiate multiple FIH¹ trials for our preclinical product candidates in 2021 Drug class Platform Oncology mRNA 13 Cell Therapies mRNA Fix Vac RiboMabs (mRNA-encoded antibodies) RiboCytokines (mRNA-encoded Cytokines) CAR-T Cells Neoantigen-based T cell therapy TCRs Infectious Disease Immunotherapies Rare Disease PRT² Product Candidate BNT116 BNT141 BNT142 BNT151 BNT 152, BNT153 BNT211 BNT212 BNT221 (NEO-PTC-01) to be selected BNT 161 undisclosed undisclosed BNT171 undisclosed Indication (Targets) NSCLC multiple solid tumors multiple solid tumors (CD3+CLDN6) multiple solid tumors (optimized IL-2) multiple solid tumors (IL-7, IL-2) multiple solid tumors (CLDN6) pancreatic, other cancers (CLDN18.2) multiple solid tumors all tumors influenza up to 10 indications HIV and tuberculosis not disclosed 4 additional rare disease indications ¹ FIH = First in Human; 2 PRT = Protein Replacement Therapy; 3 We are eligible to receive worldwide licenses Rights Collaborator fully-owned fully-owned fully-owned fully-owned Pfizer Penn³ Milestones fully-owned Phase 1 start in 1H 2021 Bill & Melinda Gates Foundation Phase 1 start in 1H 2021 Phase 1 start in 2H 2021 fully-owned Phase 1/2a start in 2H 2020 fully-owned fully-owned Phase 1 start in 1H 2021 fully-owned Genevant (global 50:50 profit/loss) Phase 1 start in 1H 2021 We expect to initiate multiple Phase 1 trials in 2021 BIONTECH#14BNT311: Next-generation bispecific antibody PD-L1x4-1BB MECHANISM OF ACTION OF Fc-SILENCED PD-L1×4-1BB BSABS ● ● 14 T cell TCR MHC-I/II + 4-1BB PD-1 PD-L1x4-1BB bsAbs PD-L1 PD-L1+ cell (tumor cell/APC) T M NK LOCAL LYMPH NODES PD-L1x4-1BB bsAbs Tumor cell Antigen-presenting cell T cell Myeloid cell Natural killer cell Macrophage APC T TUMOR NK NK Tu First-in-class, next generation checkpoint immunotherapy designed to enhance T cell and NK cell function through conditional 4-1BB co-stimulation while simultaneously blocking T cell axis Enhances proliferation and cytokine production of activated T cells, activates immune cells in tumor-draining lymph nodes, and induces tumor regression in vivo BIONTECH#15BNT311: Safety Trial in Patients With Malignant Solid Tumors (NCT03917381) Phase 1 Dose Escalation N = 61 Metastatic or unresectable solid tumors in patients who are not candidates for standard therapy 50 mg 25 mg 80 mg 100 mg 140 mg BNT311/GEN 1046: intravenous flat dose every 3 weeks until disease progression or unacceptable toxicity 15 200 mg 400 mg Cycle Q3W 1200 mg 800 mg RP2D Study Endpoints Safety and tolerability PK/PD Anti-tumor activity Biomarkers N = Phase 2a Dose Expansion Up to 40 per cohort EC1: NSCLC ≤ 2-4L p. ICI EC2: NSCLC ≤ 2-4L ICI n. EC3: Urothelial Ca ≤ 2-4L p. ICI EC4: Endometrial Ca ≤ 2-4L ICI n. EC5: TNBC ≤ 2-4L CPI n./ p. ICI EC6: SCCHN ≤ 2-4L CPI n./ p. ICI EC7: Cervical Ca ≤ 2-4L ICI n. = p. ICI post immune checkpoint inhibition CPI n. check point inhibitor naive BIONTECH#16BNT311: Phase 1 / 2a - Dose Escalation Patient Demographics Dose Escalation Cohort Median age, years (range) Age group, n (%) <65 years ≥65 years Female, n (%) Cancer type, a n (%) Colorectal cancer Ovarian cancer Pancreatic cancer NSCLC Other Median number of prior regimens, (range) Prior treatment with PD-(L)1 inhibitor, n (%) 16 All patients N=61 59 (23, 79) 44 (72.1) 17 (27.9) 28 (45.9) 12 (19.7) 9 (14.8) 6 (9.8) 6 (9.8) 28 (45.9) 3 (1-11) 23 (37.7) ● ● A total of 61 patients were enrolled in the dose escalation part of the trial Patients were heavily pretreated, receiving a median (range) of 3 (1-11) treatments; nearly 40% had received prior PD-(L)1 treatment BIONTECH#17BNT311: Phase 1 / 2a - Safety profile TEAES occurring in ≥10% of patients ALT increased AST increased Anemia Asthenia Fatigue Hypothyroidism Back pain Decreased appetite Malignant neoplasm Nausea 0 17 Dose escalation cohort 10 TRAES occurring in ≥10% of patients Any TRAE TRAES in >10% of patients, by preferred term Transaminase elevation Hypothyroidism Fatigue 20 All grades, n (%) 43 (70.5) 16 (26.2) 11 (18.0) 8 (13.1) 30 All patients (N=61) Grade 3, n (%) 15 (24.6) 6 (9.8) 0 1 (1.6) T 40 50 Grade 4, n (%) 3 (4.9) 0 1 (1.6) 0 Grade 1 Grade 2 Grade 3 Grade 4+ 100 The most common treatment-related adverse events were transaminase elevations, hypothyroidism and fatigue Treatment-related transaminase elevations occurred in 26.2% of patients (9.8% of patients had grade 3 transaminase elevations) There were no patients with Grade 4 transaminase, or treatment-related bilirubin increases MTD has not been reached BIONTECH#18BNT311: Phase 1 / 2a - Pharmacodynamics Modulation of peripheral pharmacodynamic markers A ● ● 18 100.0- 50.0- 20.0 10.0- 5.0- 2.0- 1.0- 0.5 IFN-Y p=0.021 Lower Higher doses doses B IP-10 Wilcoxon-Mann-Whitney test. IFN, interferon; IP-10, interferon-gamma-inducible protein 10. p=0.035 Lower Higher doses doses C Proliferating (Ki67+) CD8 T cells 20.0- 10.0 5.0- 2.0 1.0- 0.5 8. Lower doses p=0.024 8 * Higher doses Data extraction: June 26, 2020. Maxim al fold-change from baseline measured during cycle 1. Lower doses correspond to dose levels ≤200 mg and higher doses correspond to dose levels 2400 mg. D Proliferating (Ki67+) effector memory CD8 T cells p=0.005 20 10- Pharmacological activity was observed across a broad range of dose levels Increased levels of peripheral IFN-g and IP-10, increased frequency of proliferating (Ki67+) total CD8 and effector memory CD8+ T cells were observed Lower Higher doses doses BIONTECH#19BNT311: Phase 1 / 2a - Anti-tumor Activity: Dose escalation Best relative change in SoD from baseline (%) Best percent change from baseline in tumor size 75 50 25 -50 -75 19 PD PD PD PD PD PD PD mg 140 mg 400 mg 1200 mg 50 mg 25 PD PD PD PD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD PD SD SD SD SD SD SD SD PD PD SD SD SD NE PR UPRbuPRD PR mg mg 80 mg 140 mg 200 mg 200 mg 800 mg 200 mg 140 mg 400 mg 140 mg 80 mg 140 mg 800 mg 800 mg 200 mg 80 mg 400 mg 50 mg 400 mg 80 mg 25 mg 140 mg 100 mg 200 mg 80 mg 1200 mg 800 mg 100 mg 1200 mg 80 mg 100 mg 400 mg 400 mg 25 Dose level 1200 800 mg 50 mg 50 mg 80 mg 200 mg 400 mg 400 mg Colorectal cancer NSCLC Ovarian cancer Pancreatic cancer Other cancer Prior PD-(L)1 800 mg 50 mg 400 mg Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients. aMinimum duration of response (5 weeks) per RECIST v1.1 not reached. bPR was not confirmed on a subsequent scan. NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response. 6 : 008 200 mg 800 mg 80 mg 80 mg → Disease control achieved in 65.6% of patients; four patients with PR Includes 4 early partial responses in TNBC (1), ovarian cancer (1), and ICI-pre treated NSCLC (2) patients 200 mg 100 mg BIONTECH 19#20BNT311: Phase 1 / 2a - Anti-tumor activity in immune checkpoint recurrent/refractory NSCLC Expansion A Best relative change in SoD from baseline (%) 50 20 25- ● 0 -25 -50- -100 PD-L1 TPS, %: BOR to prior ICI: -75- 15 PR -IPP Best change from baseline in tumor size FB---PD- PR PD NA PD SD* SD SD* SD* 45 85 PR PR PD NE UPR PR* PR* NA 10 PD NA SD 80 NA NA PD NE B Change in SoD from baseline (%) 50 25 0 -25- -50- -75- -100 3 Target lesion SoD change from baseline 9 12 Study week 15 18 BOR PD SD PR Time point response PD SD PR NA As of October 12, 2020, 24 patients were enrolled in expansion cohort 1, which includes patients with NSCLC with progression on or after ICI therapy 21 12 patients had post-baseline scans; 6 patients were still on treatment with BNT311/GEN1046, 6 patients discontinued. Preliminary efficacy in 12 patients who could be objectively assessed showed two patients who achieved confirmed PR, one with unconfirmed PR, and four patients with SD Data cut-off: October 12, 2020. *Denotes patients with ongoing treatment. aPR was not confirmed by a subsequent scan. Includes all patients who had at least one post-baseline tumor assessment (schedule is every 6 weeks), and thus could be assessed for clinical benefit; 6 of 12 patients are still on treatment. BOR, best overall response; ICI, immune checkpoint inhibitor; NA, not available, NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SoD, sum of diameters; TPS, tumor proportion score; uPR, unconfirmed partial response. BIONTECH#21● Agenda 21 Q3 Highlights BNT162 (COVID-19 vaccine program) Oncology Pipeline Update Financial Update and Outlook BIONTECH#22Third Quarter 2020 Financial Results (unaudited) - Profit and Loss 22 (in millions) ¹ Revenues resulting from collaboration and license agreements Revenues from other sales transactions Total revenues Cost of sales Gross profit Research and development expenses Sales and marketing expenses General and administrative expenses Other operating income less expenses Finance income less expenses Income taxes Loss for the period 1 Numbers have been rounded; numbers presented may not add up precisely to the totals Three months ended September 30, 2019 € 22.2 6.4 € 28.7 2020 € 59.6 7.9 € 67.5 (6.9) € 60.6 (227.7) (4.3) (23.3) 8.3 (21.1) (2.5) € (210.0) (4.3) € 24.4 (50.4) (0.7) (10.6) 0.4 6.8 0.0 € (30.1) Nine months ended September 30, 2019 € 64.3 16.3 € 80.6 2020 € 113.4 23.5 € 136.9 (18.4) € 118.5 (388.0) (7.7) (58.0) 8.6 (24.8) (0.3) € (351.7) (12.9) € 67.7 (161.0) (1.9) (34.5) 1.2 7.6 0.0 € (120.9) BIONTECH#23Third Quarter 2020 Financial Results (unaudited) - Balance Sheet Balance Sheet Position 2020 Full Year Financial Guidance 23 I Cash and cash equivalents of €990.5 million ($1,159.7 million¹) as of September 30, 2020 On July 27, 2020, BioN Tech closed an underwritten offering of 5,500,000 American Depositary Shares ("ADSs"), each representing one of BioNTech's ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of €435.0 million ($511.5 million¹) • On August 28, 2020, BioNTech and a fund associated with Temasek closed a €100.0 million ($119.2 million ¹) investment in a 4-year mandatory convertible note. Temasek and another accredited investor contributed a private investment of €123.9 million ($146.0 million¹) in ordinary shares ● On September 15, 2020 BioNTech secured grant funding of up to €375.0 million ($439.1 million¹) in milestone-based funding from the BMBF2 to support and accelerate the BNT162 vaccine program execution. As funding for the grant occurs subsequent to quarter end and is subject to draw downs, this funding is not reflected in the cash and cash equivalent. balance as of September 30, 2020 BioNTech expects net cash used in operating activities and for purchases of property, plant and equipment to be within the previously guided range of €450 million and €600 million for the full year 2020 - likely to hit upper end of range due to acquisition of manufacturing facility Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020 2 German Federal Ministry of Education (Bundesminsterium für Bildung und Forschung) BIONTECH#24Positioned for transformative 2021 ● ● ● ● ● 24 Focused on executing ongoing BNT 162 Phase 3 trial and regulatory submission processes globally Commercial preparation activities for manufacturing and global distribution progressing for BNT162 with partners Pfizer and Fosun Advancing oncology pipeline towards multiple late-stage clinical trial initiations Additional first-in-human trials of novel product candidates expected across proprietary platforms Well capitalized to deliver on key commercial, operational and pipeline milestones Transformational opportunity ahead to positively impact the world - and accelerate our long-term vision to build a next generation immunotherapy leader BIONTECH#25Q&A BIONTECH 25